To our surprise, we noted that pretreatment of AR-negative, androgen-independent prostate cancer PC-3 and DU145 cells with anti-androgen CPA greatly enhanced their sensitivity to TRAIL. The gene discussed is AR; the disease is prostate carcinoma.